24/7 Market News Snapshot 17 July, 2025 – Rocket Pharmaceuticals, Inc. Common Stock (NASDAQ:RCKT)

July 17, 2025

DENVER, Colo., 17 July, 2025 (www.247marketnews.com) – (NASDAQ:RCKT) are discussed in this article.
Rocket Pharmaceuticals, Inc. (RCKT) is drawing significant attention in the financial markets, as its stock surged to $3.25 in pre-market trading, representing a notable increase of 13.64% from the prior close of $2.86. The heightened trading volume, which currently stands at 1.84 million shares, demonstrates strong investor interest and momentum behind the stock. This breakout above critical resistance levels indicates a potential continuation of the upward trend. Investors are advised to monitor the stock closely for volatility and assess relevant support levels for strategic entry points. Understanding market sentiment and the company’s core fundamentals is essential for evaluating ongoing trading opportunities in this fast-evolving landscape.

In a significant advancement for the company, Rocket Pharmaceuticals has announced that its investigational gene therapy, RP-A601, has achieved Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA). This designation is based on compelling initial safety and efficacy results from a Phase 1 clinical trial targeting PKP2-arrhythmogenic cardiomyopathy (ACM), a serious genetic heart disorder associated with life-threatening arrhythmias and sudden cardiac events.

The RMAT designation is a pivotal milestone for Rocket Pharmaceuticals, providing the company and its patients with enhanced guidance and a streamlined review process by the FDA. “This recognition reflects our dedication to developing innovative gene therapies tailored for patients with rare, inherited cardiovascular conditions,” said Kinnari Patel, PharmD, MBA, President and Head of R&D at Rocket Pharmaceuticals.

Early results from the ongoing Phase 1 trial have been promising, showcasing improved PKP2 protein expression and favorable heart function metrics among participants. The continued success of RP-A601 holds the potential to transform care for individuals afflicted with PKP2-ACM, highlighting Rocket Pharmaceuticals’ commitment to advancing groundbreaking therapeutic solutions for serious genetic disorders.

Related news for (RCKT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.